<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3397">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730206</url>
  </required_header>
  <id_info>
    <org_study_id>S6445</org_study_id>
    <nct_id>NCT04730206</nct_id>
  </id_info>
  <brief_title>The DAWN Camostat Trial for Ambulatory COVID-19 Patients</brief_title>
  <acronym>DAWN</acronym>
  <official_title>The DAWN Camostat Trial: the Efficacy of Camostat for COVID-19 Infections Presenting to Ambulatory Care: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université de Liège</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KU Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, placebo controlled, individually randomized controlled phase III trial&#xD;
      in Primary Care, assessing the efficacy of Camostat in preventing hospital admission or death&#xD;
      in Covid-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients aged 50 years and above and diagnosed with Covid-19 upon study entry, we will&#xD;
      evaluate the efficacy of camostat on hospital admission or death within 30 days after&#xD;
      randomisation. Participants will be randomly assigned to camostat or placebo using a computer&#xD;
      generated randomisation process. Participants will be treated for 7 days, and follow-up will&#xD;
      be 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital admission for at least 24 hours or death</measure>
    <time_frame>within 30 days after randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital admission for at least 24 hours</measure>
    <time_frame>within 30 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>within 30 days after randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>over a period of 30 days after randomization</time_frame>
    <description>Time from randomization to self-reported recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>at 8 days and 30 days after randomization</time_frame>
    <description>Score on the WHO clinical progression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen administration in the home setting</measure>
    <time_frame>over a period of 30 days after randomization</time_frame>
    <description>Number of patients who had oxygen at least once</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 1 year after randomization</measure>
    <time_frame>at 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular and thromboembolic complications</measure>
    <time_frame>within 7 days and 30 days after randomization</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom duration for each individual symptom</measure>
    <time_frame>over a period of 30 days after randomization</time_frame>
    <description>Duration of symptoms reported by the patient in the patient diary as being present since randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital admission for those admitted to hospital</measure>
    <time_frame>over a period of 30 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health services usage</measure>
    <time_frame>over a period of 30 days after randomization</time_frame>
    <description>Number of contacts with general practitioners, out-of-hours services, emergency department visits, specialist assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of antibiotics</measure>
    <time_frame>over a period of 30 days after randomisation</time_frame>
    <description>Antibiotic consumption expressed in defined daily dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' quality of life</measure>
    <time_frame>at 7 days and 30 days after randomization</time_frame>
    <description>EQ-5D-5L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1306</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Camostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 200 milligram per day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 x per day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat</intervention_name>
    <description>100 milligram tablets</description>
    <arm_group_label>Camostat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral tablets, identical in size and shape</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 50 years or older;&#xD;
&#xD;
          -  Covid-19 suggestive symptoms with onset of a maximum of 5 days prior to enrolment, and&#xD;
             which cannot be explained by an alternative cause, and defined by the current&#xD;
             Sciensano case definition&#xD;
&#xD;
          -  Positive result on rapid Ag test at the time of inclusion in the study;&#xD;
&#xD;
          -  Patient is community dwelling;&#xD;
&#xD;
          -  Participant or their proxy is willing and able to give informed consent for&#xD;
             participation in the trial;&#xD;
&#xD;
          -  Participant is willing to comply with all trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hospital admission is required at the time of possible recruitment;&#xD;
&#xD;
          -  Positive PCR or rapid antigen test for SARS-CoV-2 in the last 2 months other than a&#xD;
             test at recruitment;&#xD;
&#xD;
          -  Participating in any other interventional drug clinical study before enrolment in the&#xD;
             study;&#xD;
&#xD;
          -  Known severe neurological disorder, especially seizures in the last 12 months;&#xD;
&#xD;
          -  Known allergy to camostat;&#xD;
&#xD;
          -  Previous adverse reaction to, or currently taking, camostat;&#xD;
&#xD;
          -  Patients in palliative care;&#xD;
&#xD;
          -  Pregnant women or women of childbearing potential who may become pregnant during the&#xD;
             trial and don't agree to use any of the effective contraceptive measures lised above;&#xD;
&#xD;
          -  Judgement of the recruiting clinician deems participant ineligible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KU Leuven</investigator_affiliation>
    <investigator_full_name>Ann Van den Bruel</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

